Application 021342
- Type
- NDA
- Sponsor
- CEDIPROF INC
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | LEVO-T | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | No | No |
| 002 | LEVO-T | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | No | No |
| 003 | LEVO-T | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | No | No |
| 004 | LEVO-T | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | No | No |
| 005 | LEVO-T | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | No | No |
| 006 | LEVO-T | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | No | No |
| 007 | LEVO-T | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | No | No |
| 008 | LEVO-T | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | No | No |
| 009 | LEVO-T | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | No | No |
| 010 | LEVO-T | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | No | No |
| 011 | LEVO-T | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | No | No |
| 012 | LEVO-T | LEVOTHYROXINE SODIUM | TABLET;ORAL | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N021342-001 | LEVO-T | LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | |
| N021342-002 | LEVO-T | LEVOTHYROXINE SODIUM | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | |
| N021342-003 | LEVO-T | LEVOTHYROXINE SODIUM | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | |
| N021342-004 | LEVO-T | LEVOTHYROXINE SODIUM | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | |
| N021342-005 | LEVO-T | LEVOTHYROXINE SODIUM | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | |
| N021342-006 | LEVO-T | LEVOTHYROXINE SODIUM | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | |
| N021342-007 | LEVO-T | LEVOTHYROXINE SODIUM | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | |
| N021342-008 | LEVO-T | LEVOTHYROXINE SODIUM | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | |
| N021342-009 | LEVO-T | LEVOTHYROXINE SODIUM | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | |
| N021342-010 | LEVO-T | LEVOTHYROXINE SODIUM | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | |
| N021342-011 | LEVO-T | LEVOTHYROXINE SODIUM | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | |
| N021342-012 | LEVO-T | LEVOTHYROXINE SODIUM | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2003-12-08 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| N021342-001 | AB1 |
| N021342-001 | AB2 |
| N021342-001 | AB3 |
| N021342-002 | AB1 |
| N021342-002 | AB2 |
| N021342-002 | AB3 |
| N021342-003 | AB1 |
| N021342-003 | AB2 |
| N021342-003 | AB3 |
| N021342-004 | AB1 |
| N021342-004 | AB2 |
| N021342-004 | AB3 |
| N021342-005 | AB1 |
| N021342-005 | AB2 |
| N021342-005 | AB3 |
| N021342-006 | AB1 |
| N021342-006 | AB2 |
| N021342-006 | AB3 |
| N021342-007 | AB1 |
| N021342-007 | AB2 |
| N021342-007 | AB3 |
| N021342-008 | AB1 |
| N021342-008 | AB2 |
| N021342-008 | AB3 |
| N021342-009 | AB1 |
| N021342-009 | AB2 |
| N021342-009 | AB3 |
| N021342-010 | AB1 |
| N021342-010 | AB2 |
| N021342-010 | AB3 |
| N021342-011 | AB1 |
| N021342-011 | AB2 |
| N021342-011 | AB3 |
| N021342-012 | AB1 |
| N021342-012 | AB2 |
| N021342-012 | AB3 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | N021342-001 | LEVO-T | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N021342-002 | LEVO-T | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N021342-003 | LEVO-T | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N021342-004 | LEVO-T | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N021342-005 | LEVO-T | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N021342-006 | LEVO-T | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N021342-007 | LEVO-T | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N021342-008 | LEVO-T | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N021342-009 | LEVO-T | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N021342-010 | LEVO-T | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N021342-011 | LEVO-T | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N021342-012 | LEVO-T | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2003-12-08 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | N021342-001 | LEVO-T | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021342-002 | LEVO-T | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021342-003 | LEVO-T | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021342-004 | LEVO-T | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021342-005 | LEVO-T | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021342-006 | LEVO-T | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021342-007 | LEVO-T | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021342-008 | LEVO-T | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021342-009 | LEVO-T | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021342-010 | LEVO-T | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021342-011 | LEVO-T | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N021342-012 | LEVO-T | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2003-12-08 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | N021342-001 | LEVO-T | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021342-002 | LEVO-T | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021342-003 | LEVO-T | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021342-004 | LEVO-T | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021342-005 | LEVO-T | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021342-006 | LEVO-T | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021342-007 | LEVO-T | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021342-008 | LEVO-T | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021342-009 | LEVO-T | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021342-010 | LEVO-T | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021342-011 | LEVO-T | 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021342-012 | LEVO-T | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2003-12-08 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N021342-001 | LEVO-T | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021342-002 | LEVO-T | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021342-003 | LEVO-T | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021342-004 | LEVO-T | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB2,AB3 | 2002-03-01 | caaa826d4ba7… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | N021342-001 | AB1 | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-001 | AB2 | 2 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-001 | AB3 | 3 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-002 | AB1 | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-002 | AB2 | 2 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-002 | AB3 | 3 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-003 | AB1 | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-003 | AB2 | 2 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-003 | AB3 | 3 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-004 | AB1 | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-004 | AB2 | 2 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-004 | AB3 | 3 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-005 | AB1 | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-005 | AB2 | 2 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-005 | AB3 | 3 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-006 | AB1 | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-006 | AB2 | 2 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-006 | AB3 | 3 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-007 | AB1 | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-007 | AB2 | 2 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-007 | AB3 | 3 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-008 | AB1 | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-008 | AB2 | 2 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-008 | AB3 | 3 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-009 | AB1 | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-009 | AB2 | 2 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-009 | AB3 | 3 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-010 | AB1 | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-010 | AB2 | 2 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-010 | AB3 | 3 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-011 | AB1 | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-011 | AB2 | 2 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-011 | AB3 | 3 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-012 | AB1 | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-012 | AB2 | 2 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | N021342-012 | AB3 | 3 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-001 | AB1 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-001 | AB2 | 2 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-001 | AB3 | 3 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N021342-002 | AB1 | 1 | c2088c7a36db… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2019-12-13 00:20 UTC | 2019-12 | N021342-001 | 6399101 | 2020-03-30 | 74a2ff9319b5… | |||
| 2019-12-13 00:20 UTC | 2019-12 | N021342-002 | 6399101 | 2020-03-30 | 74a2ff9319b5… | |||
| 2019-12-13 00:20 UTC | 2019-12 | N021342-003 | 6399101 | 2020-03-30 | 74a2ff9319b5… | |||
| 2019-12-13 00:20 UTC | 2019-12 | N021342-004 | 6399101 | 2020-03-30 | 74a2ff9319b5… | |||
| 2019-12-13 00:20 UTC | 2019-12 | N021342-005 | 6399101 | 2020-03-30 | 74a2ff9319b5… | |||
| 2019-12-13 00:20 UTC | 2019-12 | N021342-006 | 6399101 | 2020-03-30 | 74a2ff9319b5… | |||
| 2019-12-13 00:20 UTC | 2019-12 | N021342-007 | 6399101 | 2020-03-30 | 74a2ff9319b5… | |||
| 2019-12-13 00:20 UTC | 2019-12 | N021342-008 | 6399101 | 2020-03-30 | 74a2ff9319b5… | |||
| 2019-12-13 00:20 UTC | 2019-12 | N021342-009 | 6399101 | 2020-03-30 | 74a2ff9319b5… | |||
| 2019-12-13 00:20 UTC | 2019-12 | N021342-010 | 6399101 | 2020-03-30 | 74a2ff9319b5… | |||
| 2019-12-13 00:20 UTC | 2019-12 | N021342-011 | 6399101 | 2020-03-30 | 74a2ff9319b5… | |||
| 2020-12-22 03:56 UTC | 2020-12 | N021342-001 | 6399101 | 2020-03-30 | 8869cabd3fbd… | |||
| 2020-12-22 03:56 UTC | 2020-12 | N021342-002 | 6399101 | 2020-03-30 | 8869cabd3fbd… | |||
| 2020-12-22 03:56 UTC | 2020-12 | N021342-003 | 6399101 | 2020-03-30 | 8869cabd3fbd… | |||
| 2020-12-22 03:56 UTC | 2020-12 | N021342-004 | 6399101 | 2020-03-30 | 8869cabd3fbd… | |||
| 2020-12-22 03:56 UTC | 2020-12 | N021342-005 | 6399101 | 2020-03-30 | 8869cabd3fbd… | |||
| 2020-12-22 03:56 UTC | 2020-12 | N021342-006 | 6399101 | 2020-03-30 | 8869cabd3fbd… | |||
| 2020-12-22 03:56 UTC | 2020-12 | N021342-007 | 6399101 | 2020-03-30 | 8869cabd3fbd… | |||
| 2020-12-22 03:56 UTC | 2020-12 | N021342-008 | 6399101 | 2020-03-30 | 8869cabd3fbd… | |||
| 2020-12-22 03:56 UTC | 2020-12 | N021342-009 | 6399101 | 2020-03-30 | 8869cabd3fbd… | |||
| 2020-12-22 03:56 UTC | 2020-12 | N021342-010 | 6399101 | 2020-03-30 | 8869cabd3fbd… | |||
| 2020-12-22 03:56 UTC | 2020-12 | N021342-011 | 6399101 | 2020-03-30 | 8869cabd3fbd… | |||
| 2020-11-12 02:37 UTC | 2020-11 | N021342-001 | 6399101 | 2020-03-30 | c0c555d07b60… | |||
| 2020-11-12 02:37 UTC | 2020-11 | N021342-002 | 6399101 | 2020-03-30 | c0c555d07b60… | |||
| 2020-11-12 02:37 UTC | 2020-11 | N021342-003 | 6399101 | 2020-03-30 | c0c555d07b60… | |||
| 2020-11-12 02:37 UTC | 2020-11 | N021342-004 | 6399101 | 2020-03-30 | c0c555d07b60… | |||
| 2020-11-12 02:37 UTC | 2020-11 | N021342-005 | 6399101 | 2020-03-30 | c0c555d07b60… | |||
| 2020-11-12 02:37 UTC | 2020-11 | N021342-006 | 6399101 | 2020-03-30 | c0c555d07b60… | |||
| 2020-11-12 02:37 UTC | 2020-11 | N021342-007 | 6399101 | 2020-03-30 | c0c555d07b60… | |||
| 2020-11-12 02:37 UTC | 2020-11 | N021342-008 | 6399101 | 2020-03-30 | c0c555d07b60… | |||
| 2020-11-12 02:37 UTC | 2020-11 | N021342-009 | 6399101 | 2020-03-30 | c0c555d07b60… | |||
| 2020-11-12 02:37 UTC | 2020-11 | N021342-010 | 6399101 | 2020-03-30 | c0c555d07b60… | |||
| 2020-11-12 02:37 UTC | 2020-11 | N021342-011 | 6399101 | 2020-03-30 | c0c555d07b60… | |||
| 2019-12-14 00:12 UTC | 2019-12 | N021342-001 | 6399101 | 2020-03-30 | 3f01610625f2… | |||
| 2019-12-14 00:12 UTC | 2019-12 | N021342-002 | 6399101 | 2020-03-30 | 3f01610625f2… | |||
| 2019-12-14 00:12 UTC | 2019-12 | N021342-003 | 6399101 | 2020-03-30 | 3f01610625f2… | |||
| 2019-12-14 00:12 UTC | 2019-12 | N021342-004 | 6399101 | 2020-03-30 | 3f01610625f2… | |||
| 2019-12-14 00:12 UTC | 2019-12 | N021342-005 | 6399101 | 2020-03-30 | 3f01610625f2… | |||
| 2019-12-14 00:12 UTC | 2019-12 | N021342-006 | 6399101 | 2020-03-30 | 3f01610625f2… | |||
| 2019-12-14 00:12 UTC | 2019-12 | N021342-007 | 6399101 | 2020-03-30 | 3f01610625f2… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | 66bb0ba9-cd63-4817-907f-7b8ad5dc6685 | 2026-03-27 | Boxed warning, Warnings, Adverse reactions | 021342 NDA021342 63629-2088 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | 8ac112c3-1e06-4fdb-a7af-2ee988de5b15 | 2026-03-27 | Boxed warning, Warnings, Adverse reactions | 021342 NDA021342 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | 69fb5cd6-90ba-487d-a754-07c664a1fdd1 | 2026-03-27 | Boxed warning, Warnings, Adverse reactions | 021342 NDA021342 63629-2090 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Northwind Health Company, LLC | f6c92836-95e1-1402-e053-6394a90a2f5e | 2026-01-19 | Boxed warning, Warnings, Adverse reactions | 021342 NDA021342 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Lannett Company, Inc | a8db0f7d-8863-9309-e053-2995a90a284a | 2026-01-08 | Boxed warning, Warnings, Adverse reactions | 021342 NDA021342 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Northwind Health Company, LLC | f31b5d54-7536-4290-e053-2a95a90ac235 | 2026-01-01 | Boxed warning, Warnings, Adverse reactions | 021342 NDA021342 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Northwind Health Company, LLC | f32b4a01-edea-fc85-e053-2995a90ac175 | 2026-01-01 | Boxed warning, Warnings, Adverse reactions | 021342 NDA021342 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Northwind Health Company, LLC | f31a35cb-fc54-8872-e053-2a95a90ad8e7 | 2026-01-01 | Boxed warning, Warnings, Adverse reactions | 021342 NDA021342 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Northwind Health Company, LLC | f31ba297-e042-187a-e053-2a95a90a4861 | 2026-01-01 | Boxed warning, Warnings, Adverse reactions | 021342 NDA021342 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Northwind Health Company, LLC | f31d987d-6836-b4a7-e053-2a95a90a8f7b | 2026-01-01 | Boxed warning, Warnings, Adverse reactions | 021342 NDA021342 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Northwind Health Company, LLC | f86e74e1-0d55-8d0e-e053-6394a90a07bf | 2026-01-01 | Boxed warning, Warnings, Adverse reactions | 021342 NDA021342 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Northwind Health Company, LLC | f86efc89-f784-c8bb-e053-6294a90a63c9 | 2026-01-01 | Boxed warning, Warnings, Adverse reactions | 021342 NDA021342 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Northwind Health Company, LLC | db9821db-3fe3-d1cf-e053-2a95a90a0252 | 2026-01-01 | Boxed warning, Warnings, Adverse reactions | 021342 NDA021342 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Northwind Health Company, LLC | f86fab39-bbd9-a51c-e053-6294a90accd0 | 2026-01-01 | Boxed warning, Warnings, Adverse reactions | 021342 NDA021342 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Coupler LLC | 472ec9e7-c1db-bf8c-e063-6394a90a2c07 | 2025-12-30 | Boxed warning, Warnings, Adverse reactions | 021342 NDA021342 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Coupler LLC | 4302e36f-0b5b-f645-e063-6394a90a010f | 2025-11-07 | Boxed warning, Warnings, Adverse reactions | 021342 NDA021342 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Proficient Rx LP | 9e588c43-b9b5-478e-99f7-e197add3cd26 | 2025-08-01 | Boxed warning, Warnings, Adverse reactions | 021342 NDA021342 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | A-S Medication Solutions | 91afb351-f067-49a2-bdf0-336ea209718d | 2025-05-29 | Boxed warning, Warnings, Adverse reactions | 021342 NDA021342 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | A-S Medication Solutions | 237cc591-c40b-416f-ac00-96cd61bc59dc | 2025-05-23 | Boxed warning, Warnings, Adverse reactions | 021342 NDA021342 |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | 8f83fd60-5aa7-4e7f-a6e9-917e2c1abf27 | 2024-08-21 | Boxed warning, Warnings, Adverse reactions | 021342 NDA021342 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 51655-295 | Levothyroxine Sodium | Levothyroxine Sodium | Northwind Pharmaceuticals | NDA | Current |
| 51655-299 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | Northwind Pharmaceuticals, LLC | NDA | Current |
| 51655-749 | Levothyroxine Sodium | Levothyroxine Sodium | Northwind Pharmaceuticals, LLC | NDA | Current |
| 53808-1115 | Levothyroxine sodium | Levothyroxine sodium | DOH CENTRAL PHARMACY | NDA AUTHORIZED GENERIC | Current |
| 55466-104 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-104 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-104 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-104 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-105 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-105 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-105 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-105 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-106 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-106 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-106 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-106 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-107 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-107 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-107 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-107 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-108 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-108 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-108 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-108 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-109 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-109 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-109 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-109 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-110 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-110 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-110 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-110 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-111 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-111 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-111 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-111 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-112 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-112 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-112 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-112 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-113 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-113 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-113 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-113 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-114 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-114 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-114 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-114 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-115 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-115 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-115 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 55466-115 | LEVO-T | Levothyroxine Sodium | Neolpharma, Inc. | NDA | Current |
| 61919-197 | Levothroxine Sodium | Levothroxine Sodium | Direct_Rx | NDA AUTHORIZED GENERIC | Current |
| 61919-466 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | Direct_Rx | NDA | Current |
| 61919-466 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | Direct_Rx | NDA | Current |
| 61919-549 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | Direct_Rx | NDA | Current |
| 61919-549 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | Direct_Rx | NDA | Current |
| 61919-810 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | Direct_Rx | NDA | Current |
| 61919-810 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | Direct_Rx | NDA AUTHORIZED GENERIC | Current |
| 61919-816 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | Direct_Rx | NDA | Current |
| 61919-816 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | Direct_Rx | NDA AUTHORIZED GENERIC | Current |
| 61919-870 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | Direct_Rx | NDA AUTHORIZED GENERIC | Current |
| 61919-870 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | Direct_Rx | NDA AUTHORIZED GENERIC | Current |
| 61919-872 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | DirectRx | NDA AUTHORIZED GENERIC | Current |
| 61919-872 | LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | Direct_Rx | NDA AUTHORIZED GENERIC | Current |
| 63187-851 | Levothyroxine sodium | Levothyroxine sodium | Proficient Rx LP | NDA AUTHORIZED GENERIC | Current |
| 63187-851 | Levothyroxine sodium | Levothyroxine sodium | Proficient Rx LP | NDA AUTHORIZED GENERIC | Current |
| 63187-924 | Levothyroxine sodium | Levothyroxine sodium | Proficient Rx LP | NDA AUTHORIZED GENERIC | Current |
| 63187-924 | Levothyroxine sodium | Levothyroxine sodium | Proficient Rx LP | NDA AUTHORIZED GENERIC | Current |
| 63187-924 | Levothyroxine sodium | Levothyroxine sodium | Proficient Rx LP | NDA AUTHORIZED GENERIC | Current |
| 63187-982 | Levothyroxine sodium | Levothyroxine sodium | Proficient Rx LP | NDA AUTHORIZED GENERIC | Current |
| 63187-982 | Levothyroxine sodium | Levothyroxine sodium | Proficient Rx LP | NDA AUTHORIZED GENERIC | Current |
| 63629-1837 | Levothyroxine sodium | Levothyroxine sodium | Bryant Ranch Prepack | NDA AUTHORIZED GENERIC | Current |
| 63629-1837 | Levothyroxine sodium | Levothyroxine sodium | Bryant Ranch Prepack | NDA AUTHORIZED GENERIC | Current |
| 63629-1837 | Levothyroxine sodium | Levothyroxine sodium | Bryant Ranch Prepack | NDA AUTHORIZED GENERIC | Current |
| 63629-2088 | Levothyroxine Sodium | Levothyroxine Sodium | Bryant Ranch Prepack | NDA AUTHORIZED GENERIC | Current |
| 63629-2088 | Levothyroxine Sodium | Levothyroxine Sodium | Bryant Ranch Prepack | NDA AUTHORIZED GENERIC | Current |
| 63629-2089 | Levothyroxine Sodium | Levothyroxine Sodium | Bryant Ranch Prepack | NDA AUTHORIZED GENERIC | Current |
| 63629-2089 | Levothyroxine Sodium | Levothyroxine Sodium | Bryant Ranch Prepack | NDA AUTHORIZED GENERIC | Current |
| 63629-2090 | Levothyroxine Sodium | Levothyroxine Sodium | Bryant Ranch Prepack | NDA AUTHORIZED GENERIC | Current |
Documents#
| Document | Submission type | Date |
|---|---|---|
| 85838 | SUPPL | 2026-05-21 |
| 85864 | SUPPL | 2026-05-11 |
| 50625 | SUPPL | 2017-12-07 |
| 50624 | SUPPL | 2017-12-07 |
| 27524 | SUPPL | 2011-03-11 |
| 15222 | SUPPL | 2009-06-22 |
| 27523 | SUPPL | 2009-06-17 |
| 27522 | SUPPL | 2008-06-13 |
| 27521 | SUPPL | 2008-06-13 |
| 36694 | SUPPL | 2008-06-12 |
| 15221 | SUPPL | 2008-06-12 |
| 42112 | SUPPL | 2005-05-13 |
| 42111 | SUPPL | 2005-05-13 |
| 5088 | SUPPL | 2004-06-24 |
| 5087 | SUPPL | 2004-06-24 |
| 36692 | SUPPL | 2003-12-11 |
| 5085 | SUPPL | 2003-12-11 |
| 36693 | SUPPL | 2003-08-28 |
| 5086 | SUPPL | 2003-08-28 |
| 69369 | ORIG | 2002-06-19 |
| 21609 | ORIG | 2002-06-19 |
| 27520 | ORIG | 2002-03-01 |
| 15220 | ORIG | 2002-03-01 |